RHEB GTPase has also been shown to act as a proto-oncogene in prostate cancer and up to 4% of patients with prostate cancer carry RHEB gene amplification, however RHEB oncogenic mutations are rare (≤0.1% incidence, Tables S1–S3). This evidence concerns the gene RHEB and prostate carcinoma.